Effects of cerebrolysin on moderate cognitive impairments in cerebral vascular insufficiency (a clinical-electrophysiological study)

Damulin, I V; Koberskaya, N. N.; Mkhitaryan, É. A.

doi:10.1007/s11055-008-9014-5

Cited by 9 publications

(3 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…11,12 The drug has neuroprotective and nootropic effects, enhancing neurological recovery after stroke [13][14][15] and posttraumatic brain injury 16 and improving both memory performance and cognitive functions in patients with Alzheimer's disease and vascular dementia. [17][18][19][20] Cerebrolysin has been shown to be safe and well-tolerated in clinical trials. 18,21,22 Cerebrolysin has important pharmacological actions that are relevant to its beneficial clinical effects, eg, promotion of synaptic regeneration, 23 improvement of neuronal survival, 24 protection of blood-brain barrier and blood-cerebrospinal fluid barrier, 25,26 and promotion of neural progenitor cell migration and neurogenesis.…”

Section: Introductionmentioning

confidence: 99%

Cerebrolysin protects against rotenone-induced oxidative stress and neurodegeneration

Abdel-Salam¹,

Mohammed²,

Youness³

et al. 2014

View full text Add to dashboard Cite

Abstract:We investigated the effect of cerebrolysin, a peptide mixture used for promoting memory and recovery from cerebral stroke, on the development of oxidative stress and nigrostriatal cell injury induced by rotenone administration in rats. Rotenone 1.5 mg/kg was given subcutaneously three times weekly either alone or in combination with cerebrolysin at 21.5, 43, or 86 mg/kg. Rats were euthanized 14 days after starting the rotenone injection. Lipid peroxidation (malondialdehyde), reduced glutathione (GSH), nitric oxide (nitrite) concentrations, paraoxonase 1 (PON1), and acetylcholinesterase (AChE) activities -as well as the monocyte chemoattractant protein-1 (MCP-1) and the antiapoptotic protein Bcl-2 -were measured in the brain. Histopathology, tyrosine hydroxylase, inducible nitric oxide synthase (iNOS), tumor necrosis factor-α (TNF-α), and cleaved caspase-3 immunohistochemistry were also performed. Rotenone caused a significantly elevated oxidative stress and proinflammatory response in the different brain regions. Malondialdehyde and nitric oxide concentrations were significantly increased, while GSH markedly decreased in the cerebral cortex, striatum, hippocampus, and in the rest of the brain. PON1 and AChE activities significantly decreased with respect to the control levels after rotenone application. Striatal Bcl-2 was significantly decreased while MCP-1 increased following rotenone injection. Rotenone caused prominent iNOS, TNF-α, and caspase-3 immunostaining in the striatum and resulted in markedly decreased tyrosine hydroxylase immunoreactivity in the substantia nigra and striatum. Cerebrolysin coadministered with rotenone decreased lipid peroxidation, increased GSH, and inhibited the elevation of nitric oxide induced by rotenone. Cerebrolysin also decreased the rotenone-induced decline in the PON1 and AChE activities and the rotenone-mediated changes in the striatal Bcl-2 and MCP-1 levels. The drug reduced iNOs, TNF-α, and caspase 3 expressions and increased the tyrosine hydroxylase immunoreactivity in the striatum. Cerebrolysin markedly prevented the development of neuronal damage in the cortex and striatum. These data suggest that cerebrolysin may have potential therapeutic effect in Parkinson's disease.

show abstract

Section: Introductionmentioning

confidence: 99%

Cerebrolysin protects against rotenone-induced oxidative stress and neurodegeneration

Abdel-Salam¹,

Mohammed²,

Youness³

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Cerebrolysin is considered to be an effective therapy directed to prevent further cognitive decline in people suffering from dementia, MCI, as well as older people without cognitive impairment [9] [10] [38]- [41]. However, the therapeutic effect of cerebrolysin (e.g.…”

Section: Discussionmentioning

confidence: 99%

Progression of Cognitive Deficit in Older People with Mild Cognitive Impairment Treated with Cerebrolysin

Boksha¹,

Гаврилова²,

Колыхалов³

et al. 2014

Health

View full text Add to dashboard Cite

Objectives: Although people with amnestic mild cognitive impairment (aMCI) benefit from cerebrolysin treatment, some still develop dementia. The aim of the current study was to identify most informative clinical assessment tests to predict the therapy efficacy in aMCI subjects treated with cerebrolysin. Methods: We studied patients with amnestic mild cognitive impairment (aMCI; n = 53) who had regular neurocognitive and clinical psychiatric assessments and were treated with cerebrolysin i.v. infusions 20 × 30 ml twice a year over three years period. Data were analyzed using non-parametric statistics, cluster and linear discriminant analyses. Results: Combined mathematical modeling enabled to predict cognitive decline from aMCI to dementia in the cerebrolysin-treated patients based on their initial neurocognitive assessment scores. We identified a "dementia risk group" with fast cognitive decline (i.e. low efficacy of the treatment). Lower baseline scores in the Mattis Dementia Rating Scale Memory subtest, Mini-Mental State Examination (MMSE), 10 word list immediate recall, and Frontal Assessment Battery tests when accompanied by higher depression score (Hamilton Depression Rating Scale) suggest poor prognosis for aMCI patients treated with cerebrolysin. Changes in scores on the MMSE, Boston naming test, Digit span forward, and Wechsler scale subtest "Categorical associations" during the treatment course are more characteristic for patients who convert to dementia than their initial scores. Conclusions: aMCI subjects treated with cerebrolysin with lower baseline cognitive functioning and subclinical depres-I. S. Boksha et al. 2582 sion have poor prognosis in terms of converting to dementia. Changes in the MMSE, Boston naming test, Digit span forward, and Wechsler scale subtest "Categorical associations" scores during the treatment course are more informative to identify patients who will develop dementia than their initial scores.

show abstract

“…It was reported that cerebrolysin is an effective means of treating cerebral vascular insufficiency patients. It could decrease the severity of memory and attention impairments to improve the overall cognitive status of the patients [9]. Thus, peptides derived from food could possess multiple mechanisms of action on alleviating cognitive deficits.…”

Section: Introductionmentioning

confidence: 99%

Comparison of Neuroprotective and Cognition-Enhancing Properties of Hydrolysates from Soybean, Walnut, and Peanut Protein

Li¹,

Zhao²,

Zhang³

et al. 2016

Journal of Chemistry

View full text Add to dashboard Cite

Hydrolysates were prepared from soybean, walnut, and peanut protein by papain, respectively. Their amino acid compositions and molecular weight distributions, the effects of various hydrolysates on H2O2-induced injury PC12 cells, and cognition of mice were investigated, respectively. Results showed that the three hydrolysates were dominated by the peptides with 1–3 KDa with large amount of neurotrophic amino acids. All the hydrolysates exhibited much stronger inhibitory activity against H2O2-induced toxicity than cerebrolysin, and soy protein hydrolysate showed the highest activity. Moreover, the hydrolysates also could reduce the rate of nonviable apoptotic cells at the concentration of 2 mg/mL. The test of animal’s cognition indicated that three hydrolysates could present partly better effect of improving recurred memory ability of normal mice and consolidated memory ability of anisodine-treated mice than piracetam. Therefore, soybean, walnut, and peanut protein hydrolysates were recommended as a potential food raw material for prevention or treatment of neurodegenerative disorders.

show abstract

Effects of cerebrolysin on moderate cognitive impairments in cerebral vascular insufficiency (a clinical-electrophysiological study)

Cited by 9 publications

References 12 publications

Cerebrolysin protects against rotenone-induced oxidative stress and neurodegeneration

Cerebrolysin protects against rotenone-induced oxidative stress and neurodegeneration

Progression of Cognitive Deficit in Older People with Mild Cognitive Impairment Treated with Cerebrolysin

Comparison of Neuroprotective and Cognition-Enhancing Properties of Hydrolysates from Soybean, Walnut, and Peanut Protein

Contact Info

Product

Resources

About